πŸ‡ΊπŸ‡Έ FDA
Patent

US 8481529

Combination cancer chemotherapy

granted A61KA61K31/166A61K31/5383

Quick answer

US patent 8481529 (Combination cancer chemotherapy) held by Arizona Board of Regents on Behalf of the University of Arizona expires Mon Jul 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arizona Board of Regents on Behalf of the University of Arizona
Grant date
Tue Jul 09 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
3
CPC classes
A61K, A61K31/166, A61K31/5383, A61K45/06, A61P